Urothelial Carcinoma Prognosis. In general, urothelial carcinoma is a highly treatable cancer. If found early, the cancer can be removed by surgery and usually will not come back.

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

A new combination of cancer medications appears to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard of care.. The ...

Urothelial carcinoma (UC), which can involve the urethra, bladder, and upper tracts is the sixth most commonly diagnosed cancer in Western countries. 1 Radical cystectomy (RC) with pelvic lymph ...

Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. ... The median disease-free survival was 29.6 months (95% confidence interval [CI], ...

The addition of nivolumab to cisplatin-based chemotherapy improved outcomes compared with standard regimens for certain patients with advanced urothelial carcinoma, according to the agent’s ...

Compared with chemotherapy alone, patients with unresectable or metastatic urothelial carcinoma derived a greater survival benefit with Opdivo (nivolumab) plus frontline chemotherapy with gemcitabine ...

Updated guidance offers evidence-based strategies to optimize the diagnosis and treatment of non-metastatic upper tract ...

Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer. October 28th 2022EP. 2: Unmet Needs of Patients with Locally ...

The urinary comprehensive genomic profiling (uCGP) assay (UroAmp, Convergent Genomics) had a specificity of 90% and sensitivity of 95% for an initial diagnosis of urothelial carcinoma in patients ...

Hara T, Ueki H, Okamura Y, et al. Indirect comparison of novel systemic therapies for advanced urothelial cancer using the Shiny method: a meta-analysis of phase III trials. Presented at AUA 2025 ...